‘I just don’t understand it’
NSW pharmacist and dietitian John Jones questioned Eli Lilly's direct-to-consumer platform, LillyDirect, which sells non-PBS listed medicines like Mounjaro. Jones, with 20 years of experience, owns three pharmacies and expressed concerns about the model.
How this was made
The 30-second read
Why it matters
The launch may reshape how weight‑loss medicines are accessed, affecting both Lilly's sales and pharmacy business models.
Market read
First disclosure of LillyDirect could create modest trading interest in LLY and signal a shift in drug distribution.
What to watch
Potential supply‑chain constraints and insurance coverage issues for non‑PBS drugs.
Background
Eli Lilly is expanding its reach by offering certain drugs directly to patients, bypassing traditional pharmacy channels.
Ticker impact
Eli Lilly launched LillyDirect, a direct-to-consumer platform for non‑PBS medicines such as Mounjaro, prompting concerns from a pharmacist.
potential modest upside as the service expands, but short‑term uncertainty may cause slight pressure.
First report of the launch; no financial details, but the model may shift sales channels and attract regulatory scrutiny.
Market effects
May influence other pharma companies considering direct‑to‑consumer channels.
Relevant to Australian pharmacy market and US retail pharma distribution.
Limited to Eli Lilly's product line; broader impact modest.
Counterpoint
The platform could face regulatory hurdles and limited adoption, weighing on earnings.
Key entities
- CompanyEli Lilly and Company
US‑listed pharmaceutical manufacturer (ticker LLY).
- IndividualJohn Jones
NSW pharmacist and dietitian raising concerns about the new model.
